# 跨性别女性激素治疗效果与安全性研究综述 (2020)

**来源：** Cochrane Library
**作者：** Haupt, C
**日期：** 2020

## 摘要

### 研究背景

性别焦虑症被描述为基于第一或第二性征的个体经历或表达性别与其原具有性别之间的不匹配。性别焦虑症可能与临床上重要的心理困扰有关，并可能导致改变性特征的需求。改变一个人的性特征以适应其所需性别的过程称为“转换”。

目前的指南建议使用激素和手术干预（如需要）来帮助跨性别女性（即目标为从男性过渡到女性的人）的转换。在成人中，激素疗法旨在逆转身体的男性属性并促进女性属性的发展。它通常包括雌二醇、抗雄激素或两者的组合。许多人首先单独接受激素治疗，而没有进行手术干预。然而，这并不总是足以根据需要改变诸如面部骨骼结构、乳房和生殖器等属性。对于这些跨性别女性，可以通过手术促进转换。

### 研究目的

本综述旨在评价与其他治疗方法或安慰剂治疗相比，使用抗雄激素、雌二醇或两者进行激素治疗对于跨性别女性转换的有效性和安全性。

### 检索策略

研究检索了MEDLINE、Cochrane对照试验中心注册库（Cochrane Central Register of Controlled Trials, CENTRAL）、Embase、Biosis Preview、PsycINFO和PSYNDEX。我们于2019年12月19日进行了最终检索。

### 纳入排除标准

本综述纳入研究的标准是基于16岁及以上从男性过渡到女性的跨性别女性进行的随机对照试验（randomised controlled trials, RCT）、准RCT和队列研究。与另一种形式的主动干预或安慰剂治疗对照相比，符合条件的研究评价了单独或联合使用抗雄激素和雌二醇疗法。

### 资料收集与分析

我们采用了Cochrane推荐的标准方法学程序确定研究是否具有纳入资格。

### 主要结果

我们通过数据库检索到了1057篇参考文献，在删除重复项后，我们筛选了其中的787篇。我们在全文筛选阶段检查了13项研究的纳入资格。我们排除了12项研究，并确定其中一项为正在进行的研究。我们没有检索到任何符合纳入标准的、已完成的研究。本项正在进行的研究是一项在泰国进行的比较戊酸雌二醇加环丙孕酮治疗与戊酸雌二醇加螺内酯治疗的研究。主要结局将是三个月随访时的睾酮水平。

### 作者结论

我们未找到足够的证据来确定激素治疗方法对转换期跨性别女性的有效性或安全性。研究的缺乏表明当前的临床实践和临床研究之间存在差距。需要稳健的RCT和对照队列研究来评价激素疗法（单独使用或联合使用）对转换期跨性别女性的益处和伤害。研究应特别关注受试者短期、中期和长期不良反应、生活质量及其对单独或联合使用抗雄激素和雌二醇治疗下其身体特征从男性到女性变化的满意度。研究还应关注此类激素在口服、透皮和肌肉注射时的相对作用。我们将在本综述的下一次迭代中纳入非对照队列研究，因为本综述表明此类研究能够提供该领域目前可获取的最高质量证据。届时我们将考虑其方法论局限。

## PICOs

### PICOs

###### Population (5)

-   [Adult 19-44 years](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#p=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fkk05h7rpym8z)
-   [Middle Aged 45-64 years](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#p=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fkk05h7rpym90)
-   [Young Adult 19-24 years](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#p=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fkk05h7rpym8y)
-   [Hormone Replacement Therapy](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#p=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fr4hp3psml3vt)
-   [Adolescent 13-18 years](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#p=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fkk05h7rpym8x)

###### Intervention (2)

-   [Antiandrogens](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#i=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fr4hp13qpl5s5)
-   [Estradiol](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#i=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fr4hp0r0hvbxb)

###### Comparison (3)

-   [Placebo](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#c=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fr4hp0r2dwmn5)
-   [Antiandrogens](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#c=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fr4hp13qpl5s5)
-   [Estradiol](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#c=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fr4hp0r0hvbxb)

###### Outcome (7)

-   [Sexual Satisfaction Scale for Women](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#o=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2F91dX8kEyzqsOaB)
-   [Serious Adverse Event](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#o=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2FzPmZJ5kdnrhGQG)
-   [Quality of Life Inventory](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#o=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fq02ByZ5XnMFyB6)
-   [Quality of Life](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#o=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2F3BgZRR0YwkHzkP)
-   [Body Image Quality of Life Inventory](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#o=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2F7wGmnm7ROnCqo0)
-   [Hormone Replacement Therapy](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#o=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2Fr4hp3psml3vt)
-   [Patient Satisfaction](/advanced-search/pico?p_p_id=scolarissearchresultsportlet_WAR_scolarissearchresults&p_p_lifecycle=0&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchType=basic&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchBy=9&_scolarissearchresultsportlet_WAR_scolarissearchresults_searchText=10.1002/14651858.CD013138.pub2#o=http%3A%2F%2Fdata.cochrane.org%2Fconcepts%2FZxv9Y5G78KcX2q)

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the [Cochrane Handbook](https://training.cochrane.org/handbook/current/chapter-02#section-2-3).

## 简语概要

### 激素疗法是否有助于跨性别女性进行性别重建以实现转换？

**研究背景**

跨性别女性可能会认为她们天生具有错误的性特征。这可能会导致严重的心理困扰（性别焦虑），她们希望改变自身男性身体和性特征，以符合她们经历过的女性性别。这是一个称为转换的过程。如果不采取帮助转换的措施，可能会导致跨性别女性心理压力更大。用于帮助具有男性身体的跨性别女性实现转换的医学治疗方法之一是合成女性荷尔蒙。这些激素可以通过口服、皮肤吸收或肌肉注射摄入。

**研究特征**

我们寻找纳入从男性向女性转换的跨性别女性（16岁及以上）的随机对照试验（randomised controlled trials, RCT）。RCT是一种能够降低几类偏倚可能性的研究方法。本综述纳入研究的标准是比较用于促进跨性别女性转换的不同激素治疗（单独使用雌激素、单独使用睾酮阻滞剂或雌激素联合睾酮阻滞剂），或比较该类激素治疗与安慰剂治疗（看似与实际治疗相同但不具有医疗效果的假治疗）。我们希望看到激素治疗是否有助于跨性别女性实现令她们满意的转换。我们还希望看到治疗是否存在任何健康风险。

**关键结果**

我们检索了截至2019年12月19日的研究。我们无法找到任何可以纳入的相关已完成研究。我们确实发现了一项正在进行的研究，该研究计划在2020年年底前招募所有参与研究的人。本研究比较了戊酸雌二醇加环丙孕酮治疗与戊酸雌二醇加螺内酯治疗对泰国跨性别女性的影响。

**证据质量**

我们未检索到研究激素疗法用于帮助跨性别女性转换时是否有效和安全的RCT。因此，需要高质量RCT对此类问题进行研究。

## Visual summary

## Authors' conclusions

### Implications for practice

We found insufficient evidence to determine the efficacy or safety of hormonal treatment approaches (estradiol alone or in combination with cyproterone acetate or spironolactone) for transgender women in transition. The evidence is very incomplete, demonstrating a gap between current clinical practice and clinical research.

### Implications for research

This systematic review has shown that well‐designed, sufficiently robust randomised controlled trials (RCTs) and controlled‐cohort studies do not exist, and are needed, to assess the benefits and harms of hormone therapies (used alone or in combination) for transgender women in transition. The following questions should be addressed via RCTs and cohort studies:

1.  What are the short‐, medium‐, and long‐term effects (including adverse effects, benefits, and prognoses) of estradiol therapy alone, as opposed to combination therapy using estradiol together with cyproterone acetate or spironolactone?

2.  What is the short‐, medium‐, and long‐term clinical efficacy of hormone therapy when applied orally, transdermally, and intramuscularly?

[Table 1](#CD013138-tbl-0001) presents design components that we suggest could be used in future studies. Studies should be structured and reported according to the CONSORT Statement or the STROBE Statement in order to improve the quality of reporting on efficacy and to obtain better reports on harms in clinical research ([von Elm 2007](../references/zh_HANS#CD013138-bbs2-0074 "vonElmE , AltmanDG , EggerM , PocockSJ , GøtzschePC , VandenbrouckeJP , STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.. Annals of Internal Medicine2007;147(8):573-7. [DOI: 10.7326/0003-4819-147-8-200710160-00010] [PMID: 17938396]"); [Schulz 2010](../references/zh_HANS#CD013138-bbs2-0067 "SchulzKF , AltmanDG , MoherD . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The BMJ2010;340:698-702. [DOI: 10.1136/bmj.c332]")). There is an urgent need for research in this area, not least for ethical reasons.

We will include non‐controlled cohort studies in the next iteration of this review, as this review has demonstrated that this is the highest quality evidence currently available in the field. We will take methodological limitations into account when doing so.

## Background

### Description of the condition

There is a growing trend towards de‐psychopathologisation of transgenderism ([Drescher 2014](../references/zh_HANS#CD013138-bbs2-0029 "DrescherJ . Controversies in gender diagnoses. LGBT Health2014;1(1):10-14. [DOI: 1089/lgbt.2013.1500]"); [ATME 2015](../references/zh_HANS#CD013138-bbs2-0015 "Aktion Transsexualität und Menschenrecht eV (ATME). Alternative recommendations for treatment in the presence of so-called \"sex/gender variance\". Medicine and psychotherapy without gender stereotyping. [STUTTGARTER ERKLÄRUNG - Alternative Handlungsempfehlungen bei geschlechtlichen Normvariationen]. In: In: v. Schreiber G editor(s). Transsexualität in Theologie und Neurowissenschaften ‐ Ergebnisse, Kontroversen, Perspektiven. Vol. 1. Berlin: De Gruyter, 2015:77-8. [ISBN: 978-3110440805]")). There is an emerging consensus that transgenderism is not a psychiatric disorder ([WPATH 2011](../references/zh_HANS#CD013138-bbs2-0078 "ColemanE , BocktingW , BotzerM , Cohen-KettenisP , DeCuypereG , FeldmanJ , et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people version 7. International Journal of Transgenderism2011;13(4):165–232. [DOI: 10.1080/15532739.2011.700873]")). For instance, the 11th Revision of the International Classification of Diseases (ICD‐11) ([WHO 2018](../references/zh_HANS#CD013138-bbs2-0076 "World Health Organisation. International classification of diseases for mortality and morbidity statistics (11th Revision). icd.who.int/en/ (accessed 30 October 2020).")) no longer classifies transgenderism as a behavioural and personality disorder, but has instead drafted the term "gender incongruence" to describe gender dysphoria.

In contrast, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM–5) ([DSM‐5 2013](../references/zh_HANS#CD013138-bbs2-0030 "American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5), Fifth edition. 1 edition. Vol. 1. Göttingen: Hogrefe, 2013. [ISBN: 9783801725990]")) describes gender dysphoria as a "marked incongruence between one’s experienced/expressed gender and assigned gender, of at least six months duration, as manifested by at least two of the following" characteristics:

-   A marked incongruence between one’s experienced/expressed gender and primary and/or secondary sex characteristics (or, in young adolescents, the anticipated secondary sex characteristics);

-   A strong desire to be rid of one’s primary and/or secondary sex characteristics because of a marked incongruence with one’s experienced/expressed gender (or, in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics);

-   A strong desire for the primary and/or secondary sex characteristics of the other gender;

-   A strong desire to be of the other gender (or some alternative gender different from one’s assigned gender);

-   A strong desire to be treated as the other gender (or some alternative gender different from one’s assigned gender);

-   A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one’s assigned gender).

Gender dysphoria has been defined as associated with "clinically significant distress or impairment in social, occupational or other important areas of functioning" ([Zucker 2016](../references/zh_HANS#CD013138-bbs2-0079 "ZuckerKJ . The DSM-5 diagnostic criteria for gender dysphoria. In: TrombettaC , LiguoriG , BertolottoM , editors(s). Management of Gender Dysphoria - A Multidisciplinary Approach. First edition. Vol. 1. Mailand: Springer, 2016:33-7. [ISBN: 978-88-470-5695-4]")), which may lead to substantial suffering in affected people ([Deutsch 2016a](../references/zh_HANS#CD013138-bbs2-0026 "DeutschM . Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. Center of Excellence for Transgender Health June 17th 2016;2nd Edition."); [Soll 2018](../references/zh_HANS#CD013138-bbs2-0070 "SollBM , Robles-GarcíaR , Brandelli-CostaA , MoriD , MuellerA , Vaitses-FontanariAM , et al. Gender incongruence: a comparative study using ICD-10 and DSM-5 diagnostic criteria. Brazilian Journal of Psychiatry2018;40(2):174-80.")). Gender dysphoria may result in the desire to modify one's physical and sexual characteristics to be consistent with those of the experienced gender. This process of adaptation is called transition.

The treatments applied in transition differ from those used for maintenance of the new sexual characteristics. Currently, there is uncertainty about the value of hormone therapy as a sole intervention, or when combined with surgery, for transition from male to female. This Cochrane Review specifically focuses on ‘transgender women in transition from male to female,' a definition that includes biological males aiming to adapt their sexual characteristics to be consonant with those of females.

A meta‐analysis that analyzed 21 studies on the prevalence of gender dysphoria (of which 12 studies contained evaluable data) estimated an overall prevalence of transgender women with gender dysphoria at 6.8 per 100,000 individuals ([Arcelus 2015](../references/zh_HANS#CD013138-bbs2-0014 "ArcelusJ , BoumanWP , Van Den NoortgateW , ClaesL , WitcombG , Fernandez-ArandaF . Systematic review and meta-analysis of prevalence studies in transsexualism. European Psychiatry2015;30(6):807-15.")).

### Description of the intervention

Current guidelines suggest hormonal and, if needed, surgical treatment of gender dysphoria in transgender women ([WPATH 2011](../references/zh_HANS#CD013138-bbs2-0078 "ColemanE , BocktingW , BotzerM , Cohen-KettenisP , DeCuypereG , FeldmanJ , et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people version 7. International Journal of Transgenderism2011;13(4):165–232. [DOI: 10.1080/15532739.2011.700873]")). Hormone therapy aims to suppress the development of, or to reverse, male attributes that have already developed. At the same time, hormones aim to develop female attributes. However, where male characteristics have already developed in adult males, such as in the bone structure of the face, hormones are not effective. Other treatments, such as surgery, would be required to change these ([WPATH 2011](../references/zh_HANS#CD013138-bbs2-0078 "ColemanE , BocktingW , BotzerM , Cohen-KettenisP , DeCuypereG , FeldmanJ , et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people version 7. International Journal of Transgenderism2011;13(4):165–232. [DOI: 10.1080/15532739.2011.700873]")).

The guidelines of the Endocrine Society working group suggest treatment with both oestrogens and antiandrogens ([Hembree 2017](../references/zh_HANS#CD013138-bbs2-0042 "HembreeWC , Cohen-KettenisP , Delemarre-van de WaalHA , GoorenL , HannemaSE , Meyer IIIWJ , et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism2017;102(11):3869-903. [DOI: 1210/jc.2017-01658]")). Oestrogens can be administered as either oral oestrogen, absorbed through transdermal estradiol patches, or by injection of estradiol valerate or estradiol cypionate. The application frequency differs depending on the patient’s reaction to the agent and the administration regimen; it could be multiple times per day or once every two weeks. Meanwhile, antiandrogens such as spironolactone or cyproterone acetate (CPA) are commonly taken orally. Additionally, it is possible to block male puberty by treatment with gonadotropin‐releasing hormone (GnRH) agonist injections ([Hembree 2017](../references/zh_HANS#CD013138-bbs2-0042 "HembreeWC , Cohen-KettenisP , Delemarre-van de WaalHA , GoorenL , HannemaSE , Meyer IIIWJ , et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism2017;102(11):3869-903. [DOI: 1210/jc.2017-01658]")).

While not every transgender woman undergoes hormone therapy in her transition, this intervention is still widely used ([Hembree 2017](../references/zh_HANS#CD013138-bbs2-0042 "HembreeWC , Cohen-KettenisP , Delemarre-van de WaalHA , GoorenL , HannemaSE , Meyer IIIWJ , et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism2017;102(11):3869-903. [DOI: 1210/jc.2017-01658]")). We know of no studies identifying the ratio of patients who undergo hormone therapy, nor do we know of studies investigating how much time passes between the start of transition (the decision to transition) and the start of hormone therapy. We are not aware of any studies on how often antiandrogens are being prescribed in addition to or instead of 17‐beta‐estradiol, how often they are being taken, or which kinds of androgens are in use besides CPA and spironolactone.

### How the intervention might work

Several hormonal substances and combinations are used clinically for hormone therapy in transitioning women. CPA is a progestin, steroidal anti‐androgen and anti‐gonadotropin that blocks the receptors for testosterone (T) and dihydrotestosterone (DHT), and thereby prevents these steroidal hormones from exerting their androgenic effects. Hence, it stops processes like body hair growth, hair loss on the head, male body fat distribution and others ([Figg 2010](../references/zh_HANS#CD013138-bbs2-0032 "FiggW , ChauCH , CindyH , SmallEJ . Drug Management of Prostate Cancer. 1 edition. New York: Springer, 2010. [ISBN: 978-1-60327-829-4]"); [WPATH 2011](../references/zh_HANS#CD013138-bbs2-0078 "ColemanE , BocktingW , BotzerM , Cohen-KettenisP , DeCuypereG , FeldmanJ , et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people version 7. International Journal of Transgenderism2011;13(4):165–232. [DOI: 10.1080/15532739.2011.700873]")). According to the World Professional Association for Transgender Health (WPATH) guidelines, it is possible to suppress puberty with GnRH analogues or progestins such as medroxyprogesterone ([WPATH 2011](../references/zh_HANS#CD013138-bbs2-0078 "ColemanE , BocktingW , BotzerM , Cohen-KettenisP , DeCuypereG , FeldmanJ , et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people version 7. International Journal of Transgenderism2011;13(4):165–232. [DOI: 10.1080/15532739.2011.700873]")).

Spironolactone acts as a weak androgen receptor antagonist ([Wenqing 2005](../references/zh_HANS#CD013138-bbs2-0075 "WenqingG , BohlCE , DaltonJT . Chemistry and structural biology of androgen receptor. Chemical Reviews2005;105(9):3352-70. [DOI: 10.1021/cr020456u]")). It also causes an increase in oestradiol levels ([Thompson 1993](../references/zh_HANS#CD013138-bbs2-0073 "ThompsonDF , CarterJR . Drug-induced gynecomastia. Pharmacotherapy Jan-Feb 1993;13(1):37-45. [PMID: 8094898]")), so that further virilisation is prevented and feminisation occurs ([WPATH 2011](../references/zh_HANS#CD013138-bbs2-0078 "ColemanE , BocktingW , BotzerM , Cohen-KettenisP , DeCu